^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RC98
i
Other names: RC98, RC98 for injection
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Rongchang Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
16d
Preclinical Pharmacokinetics and Pharmacology Study of RC98: A Programmed Cell Death Ligand 1 Monoclonal Antibody in Cynomolgus Monkeys. (PubMed, Curr Pharm Des)
These data indicate that the immune system was clearly activated. In addition, the non-clinical data could provide a basis for its efficacy evaluation in clinical trials.
PK/PD data • Preclinical • Journal
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression
|
RC98
5ms
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov)
P1, N=24, Recruiting, RemeGen Co., Ltd. | Trial primary completion date: Dec 2023 --> May 2024
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Aidixi (disitamab vedotin) • RC98
5ms
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=63, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting | N=25 --> 63 | Trial primary completion date: Dec 2022 --> Dec 2023
Enrollment closed • Enrollment change • Trial primary completion date • Metastases
|
RC98
over1year
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov)
P1, N=24, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Aidixi (disitamab vedotin) • RC98
over1year
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov)
P1, N=24, Not yet recruiting, RemeGen Co., Ltd.
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
Aidixi (disitamab vedotin) • RC98
Share via
